<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818268</url>
  </required_header>
  <id_info>
    <org_study_id>2000025475_a</org_study_id>
    <secondary_id>R01DC017439</secondary_id>
    <nct_id>NCT04818268</nct_id>
  </id_info>
  <brief_title>Sensory Memory in Speech Motor Learning</brief_title>
  <official_title>Role of Sensory Working Memory in Speech Motor Learning Aim 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed studies focus on memory for speech movements and sounds and its relation to&#xD;
      learning. Continuous theta-burst transcranial magnetic stimulation (cTBS) will be used to&#xD;
      suppress activity in a region of pre-frontal cortex associated with somatic and auditory&#xD;
      working memory (Brodmann area 46v) to test its involvement in learning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the relationship between sensory working memory and speech motor&#xD;
      adaptation using a between subjects design. Participants will be assigned to one of two&#xD;
      groups. Each group will undergo both auditory and somatosensory working memory tests. This&#xD;
      will be followed by adaptation to altered auditory feedback. Using a different group of&#xD;
      subjects, cTBS will be used to disrupt neural activity in Brodmann area 46v in ventrolateral&#xD;
      prefrontal cortex to test its involvement in adaptation. One set of tests will focus on the&#xD;
      effects of cTBS on both auditory and somatosensory working memory. A second set of tests will&#xD;
      focus on the effects of cTBS on speech motor adaptation to altered auditory feedback. Both&#xD;
      working memory and adaptation are assessed on 0 to 100 scales.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Speech Motor Learning</measure>
    <time_frame>Performance as measured at the end of learning (single day experiment)</time_frame>
    <description>Learning is assessed on a 0 to 100 scale as change in speech sounds (speech formant frequencies). A score of 100 corresponds to complete adaptation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensory Memory</measure>
    <time_frame>Single day experiment</time_frame>
    <description>Sensory Memory is measured on a 0 to 100 scale. A score of 100 corresponds to perfect memory.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Speech</condition>
  <condition>Consolidation</condition>
  <arm_group>
    <arm_group_label>Adaptation to Altered Auditory Feedback</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adaptation to Altered Auditory Feedback</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Auditory Sensory Memory</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Auditory Sensory Memory</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Somatosensory Sensory Memory</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Somatosensory Sensory Memory</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adaptation to Altered Auditory Feedback + cTBS to 46v</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adaptation to Altered Auditory Feedback + cTBS to 46v</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sensory Memory + cTBS to 46v</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sensory Memory + cTBS to 46v</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Adaptation</intervention_name>
    <description>Sensorimotor adaptation in speech</description>
    <arm_group_label>Adaptation to Altered Auditory Feedback</arm_group_label>
    <arm_group_label>Adaptation to Altered Auditory Feedback + cTBS to 46v</arm_group_label>
    <arm_group_label>Auditory Sensory Memory</arm_group_label>
    <arm_group_label>Sensory Memory + cTBS to 46v</arm_group_label>
    <arm_group_label>Somatosensory Sensory Memory</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cTBS</intervention_name>
    <description>continuous theta-burst stimulation</description>
    <arm_group_label>Adaptation to Altered Auditory Feedback + cTBS to 46v</arm_group_label>
    <arm_group_label>Sensory Memory + cTBS to 46v</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  right handed adults&#xD;
&#xD;
          -  no known physical or neurological abnormalities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with:&#xD;
&#xD;
          -  cardiac pacemaker&#xD;
&#xD;
          -  surgical clips or values on the heart&#xD;
&#xD;
          -  implants&#xD;
&#xD;
          -  metal or metallic fragments in any part of the body&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  claustrophobia&#xD;
&#xD;
          -  a personal or family history of epilepsy&#xD;
&#xD;
          -  currently taking antipsychotic drugs&#xD;
&#xD;
          -  currently taking antidepressant drugs&#xD;
&#xD;
          -  currently taking antianxiety drugs&#xD;
&#xD;
          -  history of concussion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Ostry</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haskins Laboratories</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Ostry</last_name>
    <phone>2038656163</phone>
    <email>david.ostry@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>McGill Univeristy</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H3A1G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Gracco</last_name>
      <email>vincent.gracco@mcgill.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT04818268/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

